Fidia Farmaceutici strengthens its position in the Spanish market with the launch of three ophthalmic products

Laboratorio Fidia Farmacéutica will begin distibution of the three ophthalmic products it recently acquired from the multinational company Novartis.

Fidia's Spanish affiliate, Laboratorio Fidia Farmacéutica, has announced today that, starting in August 2020, it will begin distribution of the three products it acquired from Novartis through a license agreement, namely:
  • an intraocular injectable solution based on acetylcholine
  • an ophthalmic ointment that combines chloramphenicol and dexamethasone
  • eye drops and ointment containing dexamethasone

These products have a consolidated presence in the Spanish market.

The products will be available in hospital pharmacies and retail pharmacies, since they shall be prescribed by ophthalmologists and eye care professionals.


Find out more about Fidia’s product portfolio:

Go to the website


Fidia Farmaceutici has a specific module dedicated to Pharmaco-Vigilance in order to promptly reporting of suspected adverse reactions. If you suspect that you have had an adverse reaction while taking one of our products or you have found defects

Key Business Areas

Fidia operates in numerous therapeutic areas, providing specific, innovative treatments for commonly occurring pathologies with major socio-economic impact, namely:

- joint care
- ophthalmology
- active wound care
- neuroscience
- aesthetic medicine